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Abstract: Previous reports suggest that neuroendocrine disturbances in patients with traumatic
brain injury (TBI) or aneurysmal subarachnoid hemorrhage (SAH) may still develop or resolve
months or even years after the trauma. We investigated a cohort of n = 168 patients (81 patients
after TBI and 87 patients after SAH) in whom hormone levels had been determined at various
time points to assess the course and pattern of hormonal insufficiencies. Data were analyzed using
three different criteria: (1) patients with lowered basal laboratory values; (2) patients with lowered
basal laboratory values or the need for hormone replacement therapy; (3) diagnosis of the treating
physician. The first hormonal assessment after a median time of three months after the injury
showed lowered hormone laboratory test results in 35% of cases. Lowered testosterone (23.1% of
male patients), lowered estradiol (14.3% of female patients) and lowered insulin-like growth factor
I (IGF-I) values (12.1%) were most common. Using Criterion 2, a higher prevalence rate of 55.6%
of cases was determined, which correlated well with the prevalence rate of 54% of cases using the
physicians’ diagnosis as the criterion. Intraindividual changes (new onset insufficiency or recovery)
were predominantly observed for the somatotropic axis (12.5%), the gonadotropic axis in women
(11.1%) and the corticotropic axis (10.6%). Patients after TBI showed more often lowered IGF-I
values at first testing, but normal values at follow-up (p < 0.0004). In general, most patients remained
stable. Stable hormone results at follow-up were obtained in 78% (free thyroxine (fT4) values) to
94.6% (prolactin values).
Keywords: hypopituitarism; traumatic brain injury; subarachnoid hemorrhage; neuroendocrinology;
posttraumatic hypopituitarism
1. Introduction
Neuroendocrine disturbances are common after brain damage [1,2]. In previous reports with
repeated hormone measurements, it has been found that neuroendocrine disturbances may still
develop or improve months or even years after traumatic brain injury (TBI). While it is more common
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for hormonal disturbances to resolve, in a few cases, new insufficiencies developed with a latency of
12 months after injury [3,4] or after three years [5]. Recently, this finding was confirmed in a cohort
of 82 Greek patients. In this cohort, pituitary insufficiency resolved in 10 out of 82 patients, whereas
hypopituitarism was newly diagnosed in 16 cases [6]. In contrast to previous reports, more patients
developed a new insufficiency than recovered from posttraumatic hypopituitarism. However, in this
study, the mean follow-up time of four years was longer than in previous reports.
Hypothalamo-pituitary dysfunction is not only observed after TBI, but also after aneurysmal
subarachnoid hemorrhage (SAH) [1,7,8]. When patients were investigated in the very early acute
phase, hypopituitarism was reported to be rare after a median follow-up time of 30 months [9].
However, recent data suggest that there might be an increase of hypopituitarism from 34% to 41%
within a two-year follow-up period [10]. Similar to TBI, recovery from pituitary insufficiency, as well
as new onset hypopituitarism is documented after one and three years following SAH [11]. Therefore,
some authors conclude that follow-up testing is mandatory in these patients [4,11].
In the classic pathologies that lead to hypopituitarism, such as intra- and supra-sellar tumors,
the return of pituitary function is very unlikely after a certain amount of time. In such patients, the
necessity of long-term hormone replacement can be prognosticated. However, given the fact that
neuroendocrine function in patients after SAH or TBI can be considered as fluctuating to a certain
degree, the indication for hormone replacement must be checked on a regular basis in order to
prevent under-, but also over-treatment. This is exemplified by case reports by Agha et al. [12] and
Streetz-van der Werf et al. [13], which highlight the consequences of over- or under-treating patients
with neuroendocrine damage after TBI.
Against this background, we analyzed our cohort of patients in the Structured Data Assessment
of Hypopituitarism after TBI and SAH to assess the prevalence and time course of neuroendocrine
disturbances across the documented follow-up period.
The Structured Data Assessment of Hypopituitarism after TBI and SAH database is a
multi-center database of TBI and SAH patients in which detailed clinical endocrine and outcome
information has been collected. It offers the possibility of the inclusion of several follow-up
assessments in order to characterize patients’ long-term course after the injury.
2. Results
2.1. Subjects with Repeated Hormone Measurements
In the Structured Data Assessment after TBI and SAH, a follow-up was conducted in 242 out of
1242 patients (117 patients after TBI and 125 patients after SAH). Since 36 patients (22 after TBI and
14 after SAH) received more than one longitudinal evaluation, a total number of 310 follow-up study
sheets (167 sheets in patients after TBI and 143 sheets in patients after SAH) were available.
After quality control, we included only cases in which hormonal assessment had been repeated;
follow-up study sheets with completion of hormonal values, but without repeated measurements
were not defined as longitudinal findings and therefore excluded. Since changes in pituitary function
require time to become manifest in laboratory values, we excluded all cases with a time interval of
<2 weeks between primary examination and follow-up. Further exclusion criteria are displayed in
the supplementary Figure S1. Using these criteria, 217 follow-up study sheets (119 follow-up study
sheets in n = 81 patients after TBI, as well as 98 follow-up study sheets in n = 87 patients after SAH)
remained for further analyses.
All 168 patients were investigated at least twice. In 22 out of 168 patients, evaluation was
conducted at least thrice and in eight patients at least four times. One single patient after TBI was
followed up to nine times.
The study sheets contained amongst other data information on current medication and basal
hormonal laboratory values (cortisol, free thyroxine (fT4), testosterone, estradiol, prolactin and
insulin-like growth factor I (IGF-I)). Basal laboratory values were documented in 144 patients out
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of 168 patients. In addition, the treating physicians had been asked at the time of data entry
to classify their patients as pituitary sufficient or insufficient with regard to the corticotropic,
thyrotropic, gonadotropic and somatotropic axis. This decision was driven not only by the basal
hormonal laboratory values, but also by the patient‘s history and clinical symptoms and signs of
hypopituitarism. All physicians were aware of the basal laboratory values of their patients, but
they were able to utilize further diagnostic information. This physicians’ diagnosis was available
in 113 patients.
2.2. Basal Laboratory Values
In n = 123 patients, all neuroendocrine parameters (cortisol, fT4, testosterone or estradiol,
respectively, prolactin and IGF-I) were documented at the first time of testing. In most patients
(n = 80/123; 65.0%), the first hormonal assessment was normal. In 38 patients (30.9%), hormone
parameters of a single pituitary axis were affected. n = 5 patients (4.1%) showed abnormal test results
indicative of an impairment of two or more pituitary axes. The first hormonal assessment after a
median time of three months after injury showed mainly low testosterone, estradiol and IGF-I values,
possibly pointing towards gonadotropic and somatotropic insufficiencies (Figure 1). At follow-up
after a median time of seven months after the injury, the prevalence rates of lowered hormonal values
decreased (Figure 1). Especially in men, sex steroids often returned to normal, indicating a recovery
of the respective hormone axis.
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2.3. Patients on Hormone Replacement Therapy 
Since our study has a naturalistic design, patients on hormone replacement therapy had also 
been included in the database. However, these patients had often normal basal laboratory values. 
Nevertheless, they suffered from pituitary insufficiency, which required a hormone replacement 
therapy. In order to have better insight into the prevalence of pituitary insufficiency after TBI and 
SAH, patients with lowered basal laboratory values, as well as patients requiring hormone 
replacement therapy with normal basal laboratory values were analyzed together and defined as 
“pituitary insufficient”. 
Using this criterion, higher prevalence rates of disturbed hormonal axes indicative of pituitary 
insufficiency were observed. In most patients (44.4%), basal laboratory values were normal at the 
first hormonal assessment. In 61 patients (42.4%), a single pituitary axis was affected, which was 
indicated by a lowered basal laboratory value or hormone replacement therapy. n = 18 patients 
(12.5%) showed an impairment of two or more pituitary axes. One patient (0.7%) receiving hormone 
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Using this criterion, higher prevalence rates of disturbed hormonal axes indicative of pituitary
insufficiency were observed. In most patients (44.4%), basal laboratory values were normal at
the first hormonal assessment. In 61 patients (42.4%), a single pituitary axis was affected, which
was indicated by a lowered basal laboratory value or hormone replacement therapy. n = 18
patients (12.5%) showed an impairment of two or more pituitary axes. One patient (0.7%) receiving
hormone replacement therapy showed further lowered laboratory neuroendocrine parameters, thus
indicating panhypopituitarism.
The first hormonal assessment after a median time of three months after injury showed
mainly results indicative of gonadotropic and of corticotropic insufficiencies (Figure 2). A
follow-up after a median time of seven months after the injury revealed fewer results indicative
of gonadotropic insufficiencies in men and a lower prevalence of assumed somatotropic and
lactotropic insufficiencies. Interestingly, the prevalence rates of assumed corticotropic and thyrotropic
insufficiencies remained stable (Figure 2).
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Figure 2. Pituitary insufficiencies defined by lowered basal laboratory values or receiving hormone
replacement in the first hormonal assessment after a median of three months (first test) and the
follow-up after a median of seven months (second test) in patients after traumatic brain injury (TBI)
and subarachnoid hemorrhage (SAH).
Using pathol gical hormone levels or the need for hormone therapy as the criterion for pituitary
insufficiency, prevalence rates did not differ significantly betwee TBI and SAH patients, except for
lowered IGF-I values at follow- p. Lowered IGF-I values were observed in 26% in patients after TBI
and in 8.3% in patients after SAH at follow-up (p = 0.007).
Moreover, intraindividual changes were observed after taking all follow-up tests into account
and not only the second hormonal assessment. Most patients remained stable (insufficient or not)
regarding the lactotropic axis (94.6%), which is clinically not so important. In other pituitary axes,
stable results were mainly obtained in 77.8% to 84.5%. Because of the high percentage of unknown
hormone replacement therapies with testosterone in men, data on this hormone in men can ot be
compared to the other pituitary axes.
Hormone changes or changes in hormone replacement indicative of new onset insufficiency or
recovery were predominantly observed in the somatotropic axis (12.5%) and in the corticotropic axis
(10.6%). Further details are shown in Table 1.
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Table 1. Intraindividual changes in pituitary insufficiencies defined by basal laboratory values or by
the change of hormone replacement therapy between the first visit and the follow-up.
Impaired Hormonal Axes Corticotropic Thyrotropic Gonadotropic Somatotropic Lactotropic
Number of Patients n = 123(* n = 56) %
n = 126
(* n = 60) %
n = 118
(* n = 36) %
n = 112
(* n = 52) %
n = 111
(* n = 52) %
Stable, no insufficiency 88 71.5 79 62.7 23 19.5 87 77.7 104 93.7
Stable, insufficiency 16 13.0 19 15.1 12 10.2 6 5.4 1 0.9
New insufficiency 10 8.1 7 5.6 2 1.7 5 4.5 2 1.8
Resolved 3 2.4 4 3.2 2 1.7 9 8.0 4 3.6
Unknown replacement 6 4.9 17 13.5 79 66.9 5 4.5 0 0.0
* Number of female patients.
In order to compare the group of patients with a stable result to the group of patients
who showed changes in basal hormone measurements or hormone replacement therapy, we
performed statistical analyses. Logistic regression analyses for the category of “change” in hormonal
values/hormone replacement therapy were performed for each pituitary axis. The variables
considered influential included “age at injury”, “sex”, “time between injury and first testing”, “type
of injury” and “pituitary insufficiency at first visit”. There were no significant results except for the
somatotropic axis in patients after TBI. Patients after TBI showed statistically more often lowered
IGF-I values at first testing, but normal values at follow-up (p < 0.0004).
2.4. Physicians’ Diagnosis of Pituitary Insufficiency
In addition to the basal laboratory values, the treating physicians were asked to classify their
patients as pituitary insufficient or not. This information was available in 113 patients. According to
the physicians’ diagnosis, 52 patients (46%) showed no hormonal insufficiency. In 45 patients (39.8%),
a single pituitary axis was disturbed. Two or more pituitary insufficiencies were documented in 15
patients (13.3%). The aforementioned patient in whom laboratory test results were severely abnormal
and who was on hormone replacement therapy was also classified as having panhypopituitarism by
the treating physician (0.9%).
At the first visit, the most common pituitary insufficiency was corticotropic insufficiency
(29.6%) followed by gonadotropic insufficiency (21.4%) (Figure 3). At follow-up, the prevalence of
corticotropic and thyrotropic insufficiencies increased up to 34% or 13%, respectively, whereas the
prevalence of gonadotropic and somatotropic insufficiencies decreased (Figure 3).
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Figure 3. Pituitary insufficie i defined by physicians’ diagnosis in t e first hormonal ass ssment
after a median of three months (first test) and the follow-up after a median of seven months
(second test).
Intraindividual changes are displayed in Table 2. The thyrotropic axis was the most stable
(94% without change), followed by the somatotropic axis (86.6 ), the gonadotropic axis (84.5%) and
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the corticotropic axis (77.3%). Most insufficiencies resolved in the gonadotropic axis (11.9%). New
onset insufficiencies were most common in the corticotropic axis (13.4%).
Table 2. Intraindividual changes in pituitary insufficiencies defined by the physicians’ diagnosis
between the first visit and the follow-up.
Impaired Hormonal Axes Corticotropic Thyrotropic Gonadotropic Somatotropic
Number of Patients n = 97(* n = 47) %
n = 92
(* n = 45) %
n = 84
(* n = 37) %
n = 90
(* n = 45) %
Stable, no insufficiency 55 56.7 80 87.0 63 75.0 74 82.2
Stable, insufficiency 20 20.6 7 7.6 8 9.5 4 4.4
New insufficiency 13 13.4 4 4.3 3 3.6 5 5.6
Resolved 9 9.3 1 1.1 10 11.9 7 7.8
* Number of female patients.
3. Discussion
In this study, we evaluated longitudinal findings in the Structured Data Assessment of
Hypopituitarism after TBI and SAH. Follow-up evaluation of hypopituitarism was available in a
large cohort of 168 patients with TBI and SAH.
In general, there are different ways to classify patients as hormonally insufficient. Basal
laboratory values as the criterion can provide first insights into the function of the pituitary
gland and are easy to obtain. In our cohort, 35% of patients showed lowered basal laboratory
values at the first assessment, indicating a potential dysfunction of the respective hormone axis.
Lowered sex hormone indicative of gonadotropic insufficiency and lowered IGF-I values indicative
of somatotropic insufficiency were most common. These results are in line with previous reports [1,3].
It is well known that the prevalence rates of posttraumatic hypopituitarism differ from study
to study due to different test methods and reference values [14]. In order to have better insight
into the prevalence of hypopituitarism, we established further criteria of “pituitary insufficiency”
in our study.
Since our study has a naturalistic design, patients on hormone replacement therapy had also
been included. They often showed normal laboratory values due to the fact that a hormone
replacement had been established. When patients on hormone replacement therapy had also been
classified as pituitary insufficient independent of their (mostly normal) laboratory values, a higher
prevalence rate of 55.6% was observed.
All patients were treated by experts in this research field in specialized centers. When the
criterion “physicians’ diagnosis of hormonal insufficiency” was applied, nearly the same prevalence
of posttraumatic hypopituitarism (54%) was observed. This demonstrates a good accordance
between the purely mechanistic evaluation of neuroendocrine laboratory values after cerebral injury
and the more holistic clinical and biochemical diagnosis of pituitary insufficiency by the treating
doctor. Nevertheless, there was some degree of discrepancy. Regarding the different pituitary axes,
lowered sexual hormones indicative of gonadotropic insufficiency were most common followed
by lowered IGF-I values indicative of somatotropic insufficiency when basal laboratory values
were applied as the criterion for pituitary insufficiency. Similar to this, gonadotropic insufficiency
could be assumed to be the most common disorder using Criterion 2 (lowered basal hormonal
values or hormone replacement therapy). However, when the physicians’ diagnosis was applied
as the criterion, corticotropic insufficiency was the most frequently-diagnosed disorder followed
by gonadotropic insufficiency. This result emphasizes that lowered laboratory values cannot be
equalized automatically with the diagnosis of pituitary insufficiency, as it shown for the gonadotropic
axis in this report, as well as in previous studies [15]. In our study, we believe the discrepancy
between the criteria to be due to additional information available to the treating physicians from
dynamic endocrine testing. In fact, treatment guidelines recommend dynamic testing for the
evaluation of the corticotropic and somatotropic axes [2,16]. Recently, Klose et al. [17] reported that
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the diagnosis of growth hormone deficiency is highly dependent on growth hormone testing and
confirmatory testing in patients after TBI. We assume that these test results have probably influenced
the “physicians’ diagnosis”.
At follow-up after a median time of seven months after injury, the prevalence of lowered
IGF-I values indicative of somatotropic insufficiency and the prevalence of lowered sex hormones
indicative of gonadotropic insufficiency decreased. The decrease was predominantly observed when
Criterion 1 (basal laboratory values) was applied, but it was also present when Criterion 2 (basal
laboratory values/hormone replacement therapy) or Criterion 3 (physicians’ diagnosis) were used as
the definition for pituitary insufficiency. It should be kept in mind that severe critical illness can be
considered as chronic stress. In stress physiology, hypercortisolism is observed as stress response to
prolonged stress in critical illness [18,19]. However, hypercortisolism itself leads to a downregulation
of gonadotropin levels [20]. In patients recovering from their brain injury, chronic stress might
be reduced over time, which might provide a normalization of the corticotropic and gonadotropic
axes [21]. This is an important fact, because persistent hypogonadism six and 12 months after injury
is associated with worse functional and cognitive outcome in patients after TBI, as described in the
study of Wagner et al. [22].
In clinical routine, it is important for the treating physician to know if a re-testing of patients
after TBI or SAH should be recommended or not. In order to answer this question, we looked at
intraindividual changes (i.e., new onset insufficiency or recovery from hypopituitarism). In general,
most patients showed similar results in the first hormonal assessment compared to the follow-up.
In more than 77% of all cases, the results (insufficiency or no insufficiency) remained at follow-up.
Changes in the individual patient were predominantly observed in the somatotropic, gonadotropic
and corticotropic axes. Especially in patients after TBI, IGF-I values at first hormonal assessment often
returned to normal at follow-up. These facts have to be considered in the consulting and treatment of
patients after TBI and SAH.
The pathomechanisms of secondary worsening of pituitary function months to years after the
injury are still largely unresolved. A few studies provide preliminary evidence that injury-induced
hypothalamic-pituitary autoimmunity might play a role [23,24]. In analogy to the scarce data
on delayed hormonal dysfunction in patients after radiotherapy, it can also be postulated that
hypothalamic neurotransmitter pathways could be affected by the injury [25]. Last, but not least, it is
also conceivable that hormone secretion capacity decreases over time to gliotic scarring or secondary
neuronal degeneration as a consequence of the initial injury to the pituitary. Further research into this
matter is clearly needed.
The strength of our study is that we could investigate a large cohort of 168 patients with different
diagnostic criteria (laboratory values, need for a hormone replacement therapy and physicians’
diagnosis) in a multi-center study. Our study has a naturalistic design to be close to clinical routine.
Furthermore, we do not only show cross-sectional data on the hormonal situation of brain-damaged
patients, but we were also able to present longitudinal data of a large number of patients.
Nevertheless, our study has also several limitations. First, a follow-up was not generally
mandatory in all of the 1242 patients originally included into the Structured Data Assessment of
Hypopituitarism. This means that there might be a preselection of patients from the total cohort [26]
who received a follow-up testing, e.g., severely impaired patients or patients with borderline
laboratory values or clinical changes over time. These were patients who were still on treatment
after TBI and SAH and consulted their physicians. Furthermore, we did not have a predefined time
of re-testing for these patients. In addition, we did not report on stimulation tests, which can help to
diagnose especially corticotropic and somatotropic insufficiencies in a better way. In the third place,
testosterone replacement therapy was not documented in most of the male patients. Therefore, we
could not specify if the patient has a gonadotropic insufficiency despite normal laboratory values.
Hence, our results on the gonadotropic insufficiency in men according to lowered basal laboratory
values cannot be directly compared to the other pituitary axes. As the basal laboratory values were
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not evaluated in a central laboratory, we cannot demonstrate mean pituitary hormone levels per se
due to different cut-off levels and different test methods. We classified laboratory values according
to the reference values of each center. In some pituitary hormones, an age-dependent decline can be
observed. However, age-dependent reference values in adults had only been applied for IGF-I, not
for testosterone or other hormones. Finally, we were not able to include a neuropsychiatric evaluation
of our patients, although it would have been of interest to correlate neuroendocrine disturbances with
neuropsychiatric impairment.
Overall, we could show that hypopituitarism after TBI and SAH remains predominantly stable.
The conclusion that can be drawn from our study is that patients should be informed about the high
probability of chronic posttraumatic hypopituitarism. Nevertheless, there is a potential recovery from
gonadotropic and somatotropic insufficiencies, especially in patients with lowered IGF-I levels after
TBI. These facts should be considered treating patients after TBI and SAH.
4. Materials and Methods
4.1. Structured Data Assessment of Hypopituitarism
Neurological, neurosurgical and endocrinological centers in Germany (n = 13) and Austria
(n = 1) participated from 2005 to 2008 in the Structured Data Assessment of Hypopituitarism after
TBI and SAH. Data from 1242 patients were collected using a structured study sheet involving
information on clinical, radiological and hormonal parameters, as well as sociodemographic values.
These data were collected by the treating physicians in the specialized centers. It was allowed to
include patients retrospectively or to evaluate hormonal status prospectively during the study period
up until 2008. Patients were entered into the Microsoft Accessr-database management system online
after pseudonymization. All patients or their legal representatives gave written informed consent.
The study was approved by the ethics committee of the Bavarian State Chamber of Physicians in
Munich with date of 21 April 2005, and complied with the Declaration of Helsinki.
Details on the methodology were described previously by Kreitschmann-Andermahr et al. [27].
The results of the whole cohort were presented previously by Schneider et al. [26], and data on the
long-term insufficiencies after TBI and SAH were described by Krewer et al. [28].
4.2. Subject Characteristics
Subject characteristics are displayed in Table 3. The severity of disability in patients after brain
damage is indicated by the Glasgow Outcome Scale [29] with the following graduation: 1, death;
2, persistent vegetative state; 3, severe disability (conscious, but disabled); 4, moderate disability
(disabled, but independent); and 5, good recovery.
Table 3. Subject characteristics.
Type of Injury All TBI SAH p-Value ♦
Number of Patients n = 168 n = 81 n = 87 -
Sex (male/female) 87/81 57/24 30/57 <0.0004
Age * mean ˘ S.D. (years) 43 ˘ 15 40 ˘ 18 46 ˘ 10 0.013
Age # mean ˘ S.D. (years) 45 ˘ 14 43 ˘ 17 46 ˘ 10 0.103
Age # median (25th, 75th percentile) (years) 45 (38, 55) 43 (27, 56) 47 (40, 52) -
GOS median (25th, 75th percentile) 5 (4, 5) 5 (4, 5) 4 (4, 5) 0.559
BMI mean ˘ S.D. (kg/m2) 26 ˘ 5 26 ˘ 6 26 ˘ 4 0.87
1st test † median (25th, 75th percentile) (months) 3 (1, 16) 3 (1, 40) 3 (2, 9) 0.734
∆ 2nd to 1st test median (25th, 75th percentile) (months) 7 (2, 11) 4 (1, 8) 8 (5, 15) <0.0004
Abbreviations: BMI, body mass index; GOS, Glasgow Outcome Scale; * at injury; # age at first hormonal
evaluation; † time between injury and first hormonal assessment; ♦ p-value to compare patients after TBI
and SAH.
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4.3. Hormonal Assessment
Hormone levels were measured in the local laboratories of the participating centers and recorded
in the study sheets. Reference values differed from center to center in dependence of the specific
assay applied and on the local laboratory value. The following definitions of hormone deficiencies
were used according to the local laboratory reference range:
Corticotropic axis: basal cortisol below the local laboratory reference value, e.g., <62 µg/L,
<5 µg/dL or <171 nmol/L, respectively;
Gonadotropic axis in men: basal testosterone below or above the local laboratory reference value,
e.g., <9.9 and >27.8 nmol/L or <2.8 and >8 µg/L;
Gonadotropic axis in women: estradiol in women below the local laboratory value
(e.g., proliferative stage < 13 ng/L or < 18.9 pg/mL, respectively, ovulation < 86 ng/L or < 35.5 pg/mL,
respectively, luteal phase < 44 ng/L or < 22.4 pg/mL, respectively, postmenopause < 35 ng/L or
< 10 pg/mL, respectively, depending on the local laboratory); basal laboratory values in female
patients with unknown menstruation status (premenopausal or not) were excluded. If laboratory
values could not be adjusted to the menstruation cycle phase, the reference value was not clear, and
the data were therefore excluded from further analyses.
Thyrotropic axis: free thyroxine (fT4) below the local laboratory value, e.g., <12 pmol/L or
<0.93 ng/dL;
Somatotropic axis: IGF-1 level below the local age- and sex-specific reference value;
Lactotropic axis: prolactin level below the local sex-specific reference values.
Although it was recommended to investigate all pituitary axes, endocrine assessment was in
some cases incomplete. In total, n = 385 study sheets (168 study sheets from the first time of testing
and 217 follow-up study sheets) were available. In n = 15 female patients, estradiol levels could not be
adjusted to the reference values, since the menstruation cycle phase was unknown. In n = 23 female
patients, estradiol values could not be used, since it was not assessed if they were premenopausal,
perimenopausal or postmenopausal. After quality control, 327 cortisol levels, 329 fT4 levels, 151
testosterone levels (out of 193), 108 estradiol levels (out of 192), 309 prolactin levels and 313 IGF-I
levels remained for further analyses.
In n = 46 patients, a hormone replacement therapy has been established after the diagnosis
of posttraumatic hypopituitarism. n = 101/385 study sheets and the therein included laboratory
values have been measured on hormone replacement therapy. In n = 242 study sheets, a hormone
replacement therapy due to posttraumatic hypopituitarism was denied. In n = 42 patients, data
regarding a hormone replacement therapy were missing.
4.4. Statistical Analyses
The Structured Data Assessment of Hypopituitarism after TBI or SAH database and data
administration were realized by ANFOMED GmbH (Möhrendorf, Germany).
Data are displayed as the mean ˘ standard deviation if normally distributed and, otherwise, as
the median and the 25th and 75th percentiles. Differences in sex between the subgroups regarding
the subjects’ characteristics were analyzed using a χ2 test. To test for significant differences between
patients after TBI and SAH, age at injury and age at first testing were analyzed using the two-tailed
Student’s t-test. The Glasgow Outcome Scale (GOS), time at first hormonal assessment and time
interval between first and second hormonal assessment were analyzed using the Mann–Whitney
U-test.
Each patient was classified as: (1) showing no change in hormonal status over time;
(2) developing a new insufficiency over time; or (3) recovered from hypopituitarism over time. Based
on this classification, a binary logistic regression analysis was performed for several pituitary axes.
Forward stepwise regression was used, in which variables are added to the model in the order of
their statistical significance. The variables considered influential included “age at injury”, “sex”,
“time between injury and first testing”, “type of injury” and “pituitary insufficiency at first visit”.
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All statistical analyses were performed with IBM SPSS Statistics 22 (IBM Corporation, Armonk,
NY, USA).
5. Conclusions
In our study, we could show that hypopituitarism after TBI and SAH remains predominantly
stable. Patients should be informed about the high probability of chronic posttraumatic
hypopituitarism. Nevertheless, there is a potential recovery from gonadotropic and somatotropic
insufficiencies, especially in patients with lowered IGF-I levels after TBI. These facts should be
considered treating patients after TBI and SAH.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/
1/2/s1.
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